Literature DB >> 19251671

Levodopa-induced dyskinesia and striatal signaling pathways.

Antonio Pisani1, Jie Shen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19251671      PMCID： PMC2651244          DOI： 10.1073/pnas.0900802106

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  22 in total

1.  A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.

Authors:  O Rascol; D J Brooks; A D Korczyn; P P De Deyn; C E Clarke; A E Lang
Journal:  N Engl J Med       Date:  2000-05-18       Impact factor: 91.245

Review 2.  Epidemiology of neurodegeneration.

Authors:  Richard Mayeux
Journal:  Annu Rev Neurosci       Date:  2003-01-24       Impact factor: 12.449

3.  RasGRP, a Ras guanyl nucleotide- releasing protein with calcium- and diacylglycerol-binding motifs.

Authors:  J O Ebinu; D A Bottorff; E Y Chan; S L Stang; R J Dunn; J C Stone
Journal:  Science       Date:  1998-05-15       Impact factor: 47.728

4.  6-Hydroxy-dopamine induced degeneration of central monoamine neurons.

Authors:  U Ungerstedt
Journal:  Eur J Pharmacol       Date:  1968-12       Impact factor: 4.432

Review 5.  Pathophysiology of levodopa-induced dyskinesia: potential for new therapies.

Authors:  E Bezard; J M Brotchie; C E Gross
Journal:  Nat Rev Neurosci       Date:  2001-08       Impact factor: 34.870

6.  Dysregulation of CalDAG-GEFI and CalDAG-GEFII predicts the severity of motor side-effects induced by anti-parkinsonian therapy.

Authors:  Jill R Crittenden; Ippolita Cantuti-Castelvetri; Esen Saka; Christine E Keller-McGandy; Ledia F Hernandez; Lauren R Kett; Anne B Young; David G Standaert; Ann M Graybiel
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-26       Impact factor: 11.205

7.  D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2/MAP kinase.

Authors:  Charles R Gerfen; Shigehiro Miyachi; Ronald Paletzki; Pierre Brown
Journal:  J Neurosci       Date:  2002-06-15       Impact factor: 6.167

Review 8.  Animal models of neurological deficits: how relevant is the rat?

Authors:  M Angela Cenci; Ian Q Whishaw; Timothy Schallert
Journal:  Nat Rev Neurosci       Date:  2002-07       Impact factor: 34.870

9.  Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function.

Authors:  Erwan Bézard; Sandrine Ferry; Ulrich Mach; Holger Stark; Ludovic Leriche; Thomas Boraud; Christian Gross; Pierre Sokoloff
Journal:  Nat Med       Date:  2003-05-12       Impact factor: 53.440

10.  Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia.

Authors:  Barbara Picconi; Diego Centonze; Kerstin Håkansson; Giorgio Bernardi; Paul Greengard; Gilberto Fisone; M Angela Cenci; Paolo Calabresi
Journal:  Nat Neurosci       Date:  2003-05       Impact factor: 24.884
View more
  4 in total

1.  New therapeutic strategies targeting D1-type dopamine receptors for neuropsychiatric disease.

Authors:  Young-Cho Kim; Stephanie L Alberico; Eric Emmons; Nandakumar S Narayanan
Journal:  Front Biol (Beijing)       Date:  2015-05-13

2.  Imaging SERT Availability in a Rat Model of L-DOPA-Induced Dyskinesia.

Authors:  Michael Walker; Laura Kuebler; Chris Marc Goehring; Bernd J Pichler; Kristina Herfert
Journal:  Mol Imaging Biol       Date:  2020-06       Impact factor: 3.488

3.  Effects of noradrenergic denervation by anti-DBH-saporin on behavioral responsivity to L-DOPA in the hemi-parkinsonian rat.

Authors:  Corinne Y Ostock; David Lindenbach; Adam A Goldenberg; Elias Kampton; Christopher Bishop
Journal:  Behav Brain Res       Date:  2014-05-13       Impact factor: 3.332

4.  Untangling Cortico-Striatal Connectivity and Cross-Frequency Coupling in L-DOPA-Induced Dyskinesia.

Authors:  Jovana J Belić; Pär Halje; Ulrike Richter; Per Petersson; Jeanette Hellgren Kotaleski
Journal:  Front Syst Neurosci       Date:  2016-03-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.